Jeremy A Mazurek1, Benjamin D Horne2, Wajeeha Saeed3, Muhammad R Sardar3, Ronald Zolty3. 1. Cardiovascular Division, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA. Electronic address: jeremy.mazurek@uphs.upenn.edu. 2. Intermountain Heart Institute, Intermountain Medical Center, Murray, Utah, USA. 3. Cardiovascular Division, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Abstract
BACKGROUND: Galectin-3, a novel binding-lectin involved in inflammation and fibrosis, is elevated in heart failure and is independently predictive of mortality in this condition. We sought to evaluate galectin-3 levels and its prognostic value in patients with pulmonary hypertension (PH), a known inflammatory state, in the setting of pulmonary arterial hypertension (PAH) and in heart failure with preserved ejection fraction-associated PH (HFpEF-PH). METHODS: We measured galectin-3 levels in 76 patients with PH; 37 patients with PAH and 39 patients with HFpEF-PH. Baseline characteristics, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels were assessed. Univariate and multivariate analyses were used to assess the prognostic value of galectin-3. RESULTS: Median (IQR) galectin-3 (ng/mL) for the entire cohort was 24.65 (IQR=10.39, 32.90); 22.33 (IQR=18.94, 27.30) and 28.94 (IQR=21.67, 39.85) in the PAH and HFpEF-PH, respectively (p=0.07). After evaluation of the galectin-3 levels by tertile, mortality rates were 16% (4/25), 34.6% (9/26), and 48% (12/25) in tertiles 1-3, respectively, and Kaplan-Meier analysis revealed a significant increase in mortality across increasing galectin-3 tertiles (log-rank p=0.014). On Cox regression analysis, galectin-3 was a strong predictor of mortality on both univariate HR=2.09 per tertile (95% CI=1.21, 3.62 per tertile; p-trend=0.008) and multivariate analysis HR=2.19 per tertile (95% CI=1.06, 4.54; p-trend=0.035) after adjusting for age, sex, race, glomerular filtration rate (eGFR), NT-proBNP, medications, and aetiology of PH (PAH vs. HFpEF-PH). CONCLUSION: Galectin-3 is a strong, independent prognostic marker in PH, regardless of aetiology. Larger studies should further evaluate the role of galectin-3 as a prognostic biomarker and possible therapeutic target in PH.
BACKGROUND:Galectin-3, a novel binding-lectin involved in inflammation and fibrosis, is elevated in heart failure and is independently predictive of mortality in this condition. We sought to evaluate galectin-3 levels and its prognostic value in patients with pulmonary hypertension (PH), a known inflammatory state, in the setting of pulmonary arterial hypertension (PAH) and in heart failure with preserved ejection fraction-associated PH (HFpEF-PH). METHODS: We measured galectin-3 levels in 76 patients with PH; 37 patients with PAH and 39 patients with HFpEF-PH. Baseline characteristics, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels were assessed. Univariate and multivariate analyses were used to assess the prognostic value of galectin-3. RESULTS: Median (IQR) galectin-3 (ng/mL) for the entire cohort was 24.65 (IQR=10.39, 32.90); 22.33 (IQR=18.94, 27.30) and 28.94 (IQR=21.67, 39.85) in the PAH and HFpEF-PH, respectively (p=0.07). After evaluation of the galectin-3 levels by tertile, mortality rates were 16% (4/25), 34.6% (9/26), and 48% (12/25) in tertiles 1-3, respectively, and Kaplan-Meier analysis revealed a significant increase in mortality across increasing galectin-3 tertiles (log-rank p=0.014). On Cox regression analysis, galectin-3 was a strong predictor of mortality on both univariate HR=2.09 per tertile (95% CI=1.21, 3.62 per tertile; p-trend=0.008) and multivariate analysis HR=2.19 per tertile (95% CI=1.06, 4.54; p-trend=0.035) after adjusting for age, sex, race, glomerular filtration rate (eGFR), NT-proBNP, medications, and aetiology of PH (PAH vs. HFpEF-PH). CONCLUSION:Galectin-3 is a strong, independent prognostic marker in PH, regardless of aetiology. Larger studies should further evaluate the role of galectin-3 as a prognostic biomarker and possible therapeutic target in PH.
Authors: Catherine E Simpson; Rachel L Damico; Paul M Hassoun; Lisa J Martin; Jun Yang; Melanie K Nies; R Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Eric D Austin; D Dunbar Ivy; William C Nichols; Allen D Everett Journal: Chest Date: 2020-01-25 Impact factor: 9.410
Authors: David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman Journal: Antioxid Redox Signal Date: 2019-03-29 Impact factor: 8.401
Authors: Scott A Barman; Feng Chen; Xueyi Li; Stephen Haigh; David W Stepp; Dmitry Kondrikov; Keyvan Mahboubi; Zsuzsanna Bordan; Peter Traber; Yunchao Su; David J R Fulton Journal: Am J Respir Crit Care Med Date: 2018-06-01 Impact factor: 21.405
Authors: Scott A Barman; Xueyi Li; Stephen Haigh; Dmitry Kondrikov; Keyvan Mahboubi; Zsuzsanna Bordan; David W Stepp; Jiliang Zhou; Yusi Wang; Daniel S Weintraub; Peter Traber; William Snider; Danny Jonigk; Jennifer Sullivan; G Ryan Crislip; Joshua T Butcher; Jennifer Thompson; Yunchao Su; Feng Chen; David J R Fulton Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-02-06 Impact factor: 5.464
Authors: Marta Banaszkiewicz; Aleksandra Gąsecka; Szymon Darocha; Michał Florczyk; Arkadiusz Pietrasik; Piotr Kędzierski; Michał Piłka; Adam Torbicki; Marcin Kurzyna Journal: J Clin Med Date: 2022-01-13 Impact factor: 4.241